Evaluation of electrocardiographic and echocardiographic findings in patients with cardiomyopathy: a narrative review
DOI:
https://doi.org/10.18203/2349-3259.ijct20262511Keywords:
Cardiomyopathy, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Restrictive cardiomyopathy, ECG findings, Echocardiography, Sudden cardiac death, Heart failureAbstract
Cardiomyopathies represent a heterogeneous group of myocardial diseases characterized by structural and functional alterations of the heart muscle. These conditions are a significant cause of morbidity and mortality worldwide, frequently leading to heart failure, arrhythmias, and sudden cardiac death (SCD). Electrocardiography (ECG) and echocardiography are the cornerstone diagnostic tools in the evaluation of these conditions, providing critical information about cardiac structure, function, and electrical activity. The purpose of this narrative review is to examine the most clinically significant cardiomyopathies-dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), and restrictive cardiomyopathy (RCM)-with a focus on their epidemiology, pathophysiology, and the characteristic ECG and echocardiographic findings used in diagnosis and management. Relevant literature was identified through PubMed and major cardiology guidelines up to March 2021. Search terms included: “cardiomyopathy,” “dilated cardiomyopathy,” “hypertrophic cardiomyopathy,” “restrictive cardiomyopathy,” “ECG findings cardiomyopathy,” and “echocardiography cardiomyopathy.” HCM is the most prevalent primary cardiomyopathy with an estimated prevalence of 1 in 500 persons. Dilated cardiomyopathy (DCM) has a prevalence of approximately 1 in 2,500 and is the leading indication for cardiac transplantation. Restrictive cardiomyopathy (RCM) is the rarest of the three, accounting for approximately 2-5% of cardiomyopathy cases. Each type demonstrates distinct and clinically meaningful ECG and echocardiographic patterns. Cardiomyopathies are associated with significant cardiovascular risk, and HCM in particular remains the leading cause of SCD in young athletes in the United States. Early identification using ECG and echocardiography is essential for risk stratification and management. Distinguishing physiological cardiac remodeling from pathological disease requires comprehensive diagnostic evaluation.
References
Arbustini E, Narula N, Dec GW, Reddy KS, Greenberg B, Kushwaha S, et al. The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy. J Am College Cardiol. 2014;64(3):304-18. DOI: https://doi.org/10.1016/j.jacc.2014.05.027
Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Europ Heart J. 2013;34(33):2636-48. DOI: https://doi.org/10.1093/eurheartj/eht210
Connors LH, Sam F, Skinner M, Salinaro F, Sun F, Ruberg FL, et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: A prospective, observational cohort study. Circulation. 2016;133(3):282-90. DOI: https://doi.org/10.1161/CIRCULATIONAHA.115.018852
Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: A position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Europ Heart J. 2008;29(2):270-6. DOI: https://doi.org/10.1093/eurheartj/ehm342
Gerull B, Gramlich M, Atherton J, McNabb M, Trombitás K, Sasse-Klaassen S, et al. Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nature Genetics. 2002;30(2):201-4. DOI: https://doi.org/10.1038/ng815
Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: The complexity of a diverse genetic architecture. Nature Rev Cardiol. 2013;10(9):531-47. DOI: https://doi.org/10.1038/nrcardio.2013.105
Ho CY, Sweitzer NK, McDonough B, Maron BJ, Casey SA, Seidman JG, Seidman CE, Solomon SD. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation. 2010;117(17):2244-52.
Krum H, Abraham WT. Heart failure. The Lancet. 2009;373(9667):941-55. DOI: https://doi.org/10.1016/S0140-6736(09)60236-1
Kushwaha SS, Fallon JT, Fuster V. Restrictive cardiomyopathy. N Eng J Med. 1997;336(4):267-76. DOI: https://doi.org/10.1056/NEJM199701233360407
Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Society Echocardiography. 2015;28(1):1-39. DOI: https://doi.org/10.1016/j.echo.2014.10.003
Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. J Am College Cardiol. 2003;42(9):1687-713. DOI: https://doi.org/10.1016/S0735-1097(03)00941-0
Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy: Present and future, with translation into contemporary cardiovascular medicine. J Am College Cardiol. 2014;64(1):83-99. DOI: https://doi.org/10.1016/j.jacc.2014.05.003
Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, et al. Diagnosis and evaluation of hypertrophic cardiomyopathy. J Am College Cardiol. 2022;79(4):372-89. DOI: https://doi.org/10.1016/j.jacc.2021.12.002
Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Eng J Med. 2018;379(11):1007-16. DOI: https://doi.org/10.1056/NEJMoa1805689
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Europ Heart J. 2021;42(36):3599-726. DOI: https://doi.org/10.1093/eurheartj/ehab368
McNally EM, Golbus JR, Puckelwartz MJ. Genetic mutations and mechanisms in dilated cardiomyopathy. J Clin Investigat. 2013;123(1):19-26. DOI: https://doi.org/10.1172/JCI62862
Muchtar E, Blauwet LA, Gertz MA. Restrictive cardiomyopathy: Genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circulat Res. 2017;121(7):819-37. DOI: https://doi.org/10.1161/CIRCRESAHA.117.310982
Nishimura RA, Tajik AJ. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician’s Rosetta Stone. J Am College Cardiol. 1994;30(1):8-18. DOI: https://doi.org/10.1016/S0735-1097(97)00144-7
Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. J Am College Cardiol. 2020;76(25):e159-240. DOI: https://doi.org/10.1016/j.jacc.2020.08.045
Schultheiss HP, Fairweather D, Caforio ALP, Escher F, Hershberger RE, Lipshultz SE, et al. Dilated cardiomyopathy. Nature Rev Dis Primers. 2019;5(1):32. DOI: https://doi.org/10.1038/s41572-019-0084-1
Downloads
Published
How to Cite
Issue
Section
